Neuraxis, Inc. (NRXS)

Price$7.07

Value ScoreF

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)158.12%

Price vs S&P 500 (4W)-24.28%

VGM Score54.53

Market Capitalization$86.81M

All Metrics

Book Value / Share (Quarterly)$0.50

P/TBV (Annual)15.48x

Revenue Growth (3Y)10.02%

Cash Flow / Share (Quarterly)$-0.54

Price vs S&P 500 (YTD)43.02%

Gross Margin (TTM)85.00%

Net Profit Margin (TTM)-170.11%

EPS (TTM)$-0.73

10-Day Avg Trading Volume0.13M

EPS Excl Extra (TTM)$-0.73

Revenue Growth (5Y)13.08%

EPS (Annual)$-0.86

ROI (Annual)-219.88%

Gross Margin (Annual)84.23%

Net Profit Margin (5Y Avg)-281.94%

Cash / Share (Quarterly)$0.62

Revenue Growth QoQ (YoY)79.52%

ROA (Last FY)-121.81%

Revenue Growth TTM (YoY)45.88%

EBITD / Share (TTM)$-0.72

Operating Margin (TTM)-169.93%

Cash Flow / Share (Annual)$-0.62

P/B Ratio15.10x

P/B Ratio (Quarterly)14.40x

Net Income / Employee (Annual)$-325,000

EV / Revenue (TTM)18.65x

Net Interest Coverage (TTM)-73.85x

ROA (TTM)-103.99%

EPS Incl Extra (Annual)$-0.86

Current Ratio (Annual)2.05x

Quick Ratio (Quarterly)2.65x

3-Month Avg Trading Volume0.16M

52-Week Price Return159.63%

Revenue / Employee (TTM)$178,400

Tangible BV / Share (Quarterly)$0.48

P/S Ratio (Annual)24.32x

Asset Turnover (Annual)0.56x

52-Week High$9.33

Operating Margin (5Y Avg)-228.01%

EPS Excl Extra (Annual)$-0.86

CapEx CAGR (5Y)34.32%

26-Week Price Return171.71%

Quick Ratio (Annual)1.85x

13-Week Price Return11.27%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)2.89x

Enterprise Value$79.84M

Revenue / Share Growth (5Y)4.46%

Asset Turnover (TTM)0.61x

Revenue / Employee (Annual)$148,700

Inventory Turnover (Annual)3.73x

Pretax Margin (Annual)-218.55%

Cash / Share (Annual)$0.47

3-Month Return Std Dev67.83%

Gross Margin (5Y Avg)86.06%

Net Income / Employee (TTM)$-303,500

ROE (Last FY)-229.47%

Net Interest Coverage (Annual)-55.83x

EPS Basic Excl Extra (Annual)$-0.86

Receivables Turnover (TTM)13.62x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-0.73

Receivables Turnover (Annual)16.21x

ROI (TTM)-179.27%

P/S Ratio (TTM)20.28x

Pretax Margin (5Y Avg)-281.94%

Revenue / Share (Annual)$0.39

Tangible BV / Share (Annual)$0.29

Price vs S&P 500 (52W)131.48%

Year-to-Date Return54.41%

5-Day Price Return-5.91%

EPS Normalized (Annual)$-0.86

ROA (5Y Avg)-777.50%

Net Profit Margin (Annual)-218.55%

Month-to-Date Return-5.40%

Cash Flow / Share (TTM)$-2.00

EBITD / Share (Annual)$-0.86

Operating Margin (Annual)-219.37%

LT Debt / Equity (Annual)0.00x

EPS Basic Excl Extra (TTM)$-0.73

P/TBV (Quarterly)15.10x

P/B Ratio (Annual)14.23x

Inventory Turnover (TTM)4.66x

Pretax Margin (TTM)-170.11%

Book Value / Share (Annual)$0.32

Price vs S&P 500 (13W)0.61%

Beta1.47x

Revenue / Share (TTM)$0.39

ROE (TTM)-185.74%

52-Week Low$2.20

vGradeF

gGradeA

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.18est. -0.19

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — Electromedical Equipment(31)

Symbol	Value Score	Growth Score	Momentum Score	Price
NRXSNeuraxis, Inc.	F	A	B	$7.07
MDTMedtronic plc	B	D	D	$77.95
MASIMasimo Corporation	D	D	B	$178.78
LIVNLivaNova PLC Ordinary Shares	C	C	B	$71.33
ITGRInteger Holdings Corporation	B	C	C	$90.89
TMDXTransMedics Group, Inc. Common Stock	C	B	F	$69.69
AXGNAxogen, Inc. Common Stock	F	B	A	$40.63
BLFSBioLife Solutions Inc.	F	B	B	$27.25
CNMDCONMED Corporation	A	C	D	$33.06
INMDInMode Ltd. Ordinary Shares	A	D	C	$13.49
CBLLCeriBell, Inc. Common Stock	D	A	C	$17.18

About

Neuraxis Inc is a growth-stage company developing neuromodulation therapies for chronic and debilitating conditions in children and adolescents. The company's proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology targets disorders of gut-brain interaction (DGBIs) in the pediatric population.